Anti-inflammatory agents and renal function

Seminars in Arthritis and Rheumatism

Volumn 32, Issue 3 SUPPL. 1, 2002, Pages 33-42

  Brater, D Craig ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

COX 2; Coxibs; NSAIDs; Renal function

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; VALDECOXIB;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; EDEMA; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; OSTEOARTHRITIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SODIUM EXCRETION;

EID: 0036933008     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2002.37216     Document Type: Review

References (40)

1. Crofford LJ. COX-1 and COX-2 tissue expression: Implications and predictions. J Rheumatol 1997;24(suppl 49):15-9.
2. Kömhoff M. Gröne H-J, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function. Am J Physiol 1997;272:F460-F8.
3. Brater DC. Effects of nonsteroidal anti-inflammatory drugs on renal function: Focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107:65S-71S.
4. Nantel F, Meadows E, Denis D, Connolly B, Metters KM, Giaid A. Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Letters 1999;457:475-7.
5. Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-10.
6. Zhang MZ, Wang JL, Cheng HF, Harris RC, McKanna JA. Cyclooxygenase-2 in rat nephron development. Am J Physiol 1997;273(6 pt 2):F994-F1002.
7. Brater C. Renal effects of COX-2-selective inhibitors. Am J Nephrol 2001;21:1-15.
8. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
9. Carmichael J, Shankel SW. Effects of nonsteroidal antiinflammatory drugs on prostaglandins and renal function. Am J Med 1985;78:992-1000.
10. Okahara K, Sun B, Kambayashi J. Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1922-6.
11. Bustos M, Coffman TM, Saadi S, Platt JL. Modulation of eicosanoid metabolism in endothelial cells in a xenograft model. Role of cyclooxygenase-2. J Clin Invest 1997;100:1150-8.
12. Hoffman C. COX-2 in brain and spinal cord-implications for therapeutic use. Curr Med Chem 2000;7:1113-20.
13. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
14. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110:28S-32S.
15. Warner TD, Giuliano F, Vojnovic I, Bukasa A, Mitchell JA, Vane JR. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA 1999;96:7563-8.
16. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine 1984;63:165-81.
17. Kaojarem S, Chennavasin P, Anderson S, Brater DC. Nephron site of effect of nonsteroidal anti-inflammatory drugs on solute excretion in humans. Am J Physiol 1983;244:134-9.
18. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987;32:1-12.
19. Stokes JB, Kokko JP. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977;59:1099-104.
20. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications. Am J Med 1999;106:13S-24S.
21. Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
22. Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. Ann Intern Med 2000;133:1-9.
23. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999:289:735-41.
24. Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70.
25. Muther RS, Potter DM, Bennett WM. Aspirin-induced depression of glomerular filtration rate in normal humans: Role of sodium balance. Ann Intern Med 1981;94:317-21.
26. Kramer HJ, Stinnesbeck B, Klautke G, Kipnowski J, Klingmueller D, Glaenzer K, et al. Interaction of renal prostaglandins with the renin-angiotensin and renal adrenergic nervous systems in healthy subjects during dietary changes in sodium intake. Clin Sci (Lond) 1985;68:387-93.
27. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal functions: A randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
28. Geba GP, Pollis AB, Dixon ME, Dobbins TW, Rush JE, Weir MR. Comparative blood pressure effects of Rofecoxib, Celecoxib, and placebo in patients with osteoarthritis (OA): A randomized controlled trial. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic. Abstract SAT0095.
29. Schwartz JI, Malice MP, Lasseter KC, Holmes GB, Gottesdiener KM, Brune K. Effect of rofecoxib, celecoxib, and naproxen on blood pressure and urinary sodium excretion in elderly volunteers. Paper presented at: EULAR 2001; June 13-16, 2001; Prague, Czech Republic. Abstract SAT0055.
30. Johnson AG. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging 1998;12:17-27.
31. Bombardier C, Laine L, Reicin A. Shapiro D. Burgos-Vargas R. Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8. 2 p following 1528.
32. FitzGerald GA. Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
33. FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D. Cyclo-oxygenase products and atherothrombosis. Ann Med 2000;32(suppl 1):21-6.
34. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89:33D-8D.
35. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002;162:1099-104.
36. Rahme E, Pilote L, LeLorier J. Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002;162:1111-5.
37. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-8.
38. Vioxx (Rofecoxib). U.S. Product Information. 2000.
39. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: A pattern of nephrotoxicity similar to traditional non-steroidal anti-inflammatory drugs. Am J Med 2001;111:64-7.
40. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001;110 Suppl 3A:33S-42S.